Does OHP Cover GLP-1? Diabetes, Heart, MASH, and Sleep Apnea

The Oregon Health Plan does cover GLP-1 medications, but only when they are prescribed for a specific covered condition and approved in advance. OHP pays for GLP-1 and dual GLP-1/GIP receptor agonists to treat type 2 diabetes, to reduce cardiovascular risk in adults who already have heart disease, to treat moderate-to-advanced metabolic dysfunction-associated steatohepatitis (MASH), and to treat moderate-to-severe obstructive sleep apnea. It does not cover these drugs for adults who want them for weight loss alone. Members under 21 have a separate pathway that can allow weight-management coverage in narrow circumstances.

Weight Loss Alone Is Not a Covered Reason

Federal Medicaid rules let states exclude drugs prescribed solely for weight loss, and Oregon has taken that option. Trillium Community Health Plan’s pharmacy guidance states plainly that “pharmacologic treatment of obesity is an excluded benefit of the Oregon Health Plan.”¹ The state’s own drug review materials say the same.²

In practical terms, an adult cannot get Wegovy, Zepbound, Saxenda, or a similar medication through OHP just because they want to lose weight. There has to be another qualifying diagnosis, and the prior authorization process is built to verify that.

Type 2 Diabetes

OHP covers GLP-1 receptor agonists for type 2 diabetes through a step-therapy structure. Dulaglutide (Trulicity), exenatide (Byetta), and liraglutide (Victoza) are listed as preferred on the state’s fee-for-service drug list. Semaglutide (Ozempic and Rybelsus) and tirzepatide (Mounjaro) are non-preferred and carry additional prior authorization requirements.³

To get any GLP-1 approved for diabetes, a patient generally needs an HbA1c above 7%, a documented trial and failure of metformin (or a documented reason they cannot take it), and a documented history of inadequate results on liraglutide. On top of that, they must have failed three-month trials of two other diabetes drugs from a list that includes sulfonylureas, pioglitazone, alogliptin, and SGLT2 inhibitors. Mounjaro follows the same criteria rather than a separate pathway.⁴

Patients with established atherosclerotic cardiovascular disease or chronic kidney disease can skip parts of the step therapy, but they still have to show they’ve tried or cannot tolerate an SGLT2 inhibitor. Two GLP-1 or GIP agonists cannot be used together.⁴

Cardiovascular Risk Reduction

OHP covers Wegovy (semaglutide) for adults who already have heart disease and need to lower the risk of future cardiac events. This tracks the FDA’s 2023 approval of Wegovy for cardiovascular risk reduction. To qualify, a patient must be at least 45, have a BMI of 27 or higher, and have a documented history of heart attack, stroke, or symptomatic peripheral arterial disease. Diabetes must have been ruled out through screening within the past year, because patients with diabetes go through the diabetes pathway instead.⁵

Before approval, the patient must have participated in a provider-directed weight loss plan involving diet, exercise, or nutritional counseling for at least three months within the previous six. They should also be taking standard cardiovascular prevention drugs such as high-intensity statins or antiplatelet medications unless those are medically inappropriate.⁶ Initial approval runs six months. Renewal requires documented maintenance of at least a 5% BMI reduction and continued participation in a weight loss program.⁵

MASH (Fatty Liver Disease)

Wegovy is also covered for adults with non-cirrhotic MASH who have moderate to advanced liver fibrosis, meaning stage F2 or F3. Fibrosis must be confirmed by liver biopsy or by non-invasive testing such as vibration-controlled transient elastography, magnetic resonance elastography, or an Enhanced Liver Fibrosis score, each with specific threshold values.⁵

Patients with significant alcohol use are excluded, and Wegovy cannot be used at the same time as resmetirom (Rezdiffra). Patients must be actively working on diet and physical activity. Initial approval is six months; renewal for another 12 months requires clinical documentation of stable or improved fibrosis.⁵

Obstructive Sleep Apnea

Tirzepatide (Zepbound) is covered for adults without diabetes who have moderate-to-severe obstructive sleep apnea and a BMI of at least 30. The sleep apnea diagnosis must be confirmed by a polysomnography study showing an apnea-hypopnea index of 15 or more events per hour. The patient must have already maximized CPAP or BiPAP therapy or shown an inability to tolerate it, and must have participated in a provider-directed weight loss plan for at least three months within the past six.⁷

Renewal at 12 months requires evidence of at least a 5% BMI reduction, continued PAP therapy, and continued weight loss treatment.⁵

Members Under 21

The adult weight-loss exclusion has one narrow exception. OHP members under 21 can qualify for weight-management drug coverage through the federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) program, which requires Medicaid to cover medically necessary services for children and young adults even when those services are not on the standard benefit list.

The criteria generally require a member between 12 and 20 with a BMI at or above the 95th percentile for their age and sex (or a BMI of 30 or higher), active enrollment in a provider-directed weight loss program, and an FDA-approved medication for the member’s age.⁸

CareOregon’s policy for pediatric chronic weight management goes further: the patient must have severe obesity (BMI of 35 or higher, or at least 120% of the 95th percentile), must have tried phentermine/topiramate (Qsymia) first, and must have completed a documented lifestyle intervention lasting three to 12 months. Initial approval is six months, and renewal requires at least a 5% reduction in baseline BMI.⁵

EPSDT requests are reviewed case by case. The prescriber has to submit clinical documentation showing why the medication is medically necessary, why it is the least costly effective option, and what alternatives have already been tried.⁹

Your CCO Sets the Details

OHP delivers most care through coordinated care organizations, and while every CCO follows state guidelines, the specifics of prior authorization can differ. Trillium, for example, requires six months of enrollment in a physician-directed weight loss program before approving Wegovy for cardiovascular prevention, while CareOregon’s policy calls for a three-month treatment plan within the prior six months.¹⁰⁵

Check the criteria your own CCO applies before assuming a request will be approved or denied. The CCO’s name appears on your OHP identification card.

If a Prior Authorization Is Denied

A denial arrives as a Notice of Adverse Benefit Determination that explains the decision and lists your appeal rights. If you’re enrolled in a CCO, you have 60 days from the date on the notice to file an appeal with the CCO. The CCO has 16 days to decide, with an optional 14-day extension. If the medical need is urgent, you can request an expedited appeal, which must be resolved within 72 hours.¹¹

If the CCO appeal is unsuccessful, you can request an administrative hearing through the Oregon Health Authority within 120 days of the appeal resolution. Hearings can be requested online or with form OHP 3302. If a service you’re already receiving is being cut off, you can ask that it continue during the appeal, but only if you make that request within 10 days of the notice’s effective date.¹¹ You can name anyone, including your prescribing provider, to represent you. Free legal help is available through Legal Aid Services of Oregon and the Oregon Law Center’s Public Benefits Hotline at 1-800-520-5292.¹²

1
Trillium Community Health Plan. Pharmacy Information and Preferred Drug List Changes, Third Quarter 2024
2
Oregon Prescription Drug List. Weight Loss DERP Summary
3
Oregon Prescription Drug List. Oregon Fee-for-Service Enforceable Physical Health Preferred Drug List
4
CareOregon. Glucagon-Like Peptide 1 and GIP Agonists PA Criteria
5
CareOregon. GLP-1 and GIP Agonist Drugs for Non-Diabetes Indications PA Criteria
6
Oregon Prescription Drug List. Semaglutide CV Risk PA Update
7
Oregon Prescription Drug List. Tirzepatide OSA PA Update
8
Trillium Community Health Plan. Weight Management Drugs Clinical Policy
9
Oregon Health Authority. EPSDT Provider Guide
10
Trillium Community Health Plan. Semaglutide (Wegovy) Clinical Policy
11
Oregon Health Authority. Appeals and Hearings
12
Health Share of Oregon. Complaints and Appeals